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INTRODUCTION 
Solid organ transplantation (heart, lung, liver, kidney, pancreas and intestine) has become a 
successful and widely accepted treatment for a variety of conditions. However, the shortage of 
cadaveric organs is hindering the larger use of this therapeutic option. In spite of the progressive 
evolution of public and professional understanding and acceptance of organ donation during the past 30 
years, only a little over 25 % of all potential organ donors will actually come to donation 1-3. As of 
May 31. 1993, there were 31,354 patients on the United Network for Organ Sharing (UNOS) waiting 
list4, representing an increase of 325% from December, 1986 (9,632). At the same time. the supply of 
organ donors underwent a marginal increase between 1986 and 1991 (from approximately 4,000 to 
4.500), and has been stable in the past 2 years. with 4.534 in 19925-7 (Figure 1). It is also estimated 
that every day seven potential organ recipients in the United States will die before a suitable organ is 
found8. Consequently, while the need has increased dramatically, we observe with mounting concern 
the persistent wastage of available organs. and the death of potential recipients. These are both mainly 
related to unwillingness to donate, or a lack of awareness regarding donation. as well as delays or 
failure by the medical staff to consider organ donation3. In addition, there are other forces at work that 
have signiticantly decreased organ availability for the sicker patients, such as a policy implemented by 
UNOS in 1991 that substantially changed previous allocation criteria9. As a result of this. there is now 
an even more limited number of organs available for the most severely ill patients. and some advocate 
their outright exclusion from transplant candidacy, in favor of the elective cases 10. 
Many routes have been explored in an attempt to remedy this situation. including the 
uevelopment of artiticial organs 11, utilization of living donors even for extra-renal organs 12.13, 
xenotransplantation 14-17, and non-heartbeating donors 18. However. a more immediate impact on 
organ shonage could be effected by improving our current mechanisms for organ recovery, and the 
management of potential donors. 
ORGAN RECOVERY 
Standardized criteria for the determination of brain death were defined by the Ad Hoc 
Committee of the Harvard Med ical School 19 , and have been the subject of a more recent report20. The 
concept of brain death and the management of the brain dead donor are discussed in detail in Chapter 2 
(Section XV). 
Once a potential organ donor is identified, the multiple organ procurement process should be 
triggered. This starts by contacting the local Organ Procurement Organization (OPO) as soon as the 
irreversibility of brain injury has been established. As of 1992, the 68 OPO and 266 transplant centers 
in the United States represented the largest organ procurement and transplant network in the world. 
Most intensive care units have the telephone number of the local agency available. However, the 
phone number and location of the area's OPO can be obtained from the UNOS. who has a 24-hour 
phone line EUMM-O4P~TFK These OPOs, originally set up to organize the recovery of kidneys, 
coordinate the complex logistics of multiple organ recovery, and their distribution within a 
predetermined geographical area. They are also responsible for the payment of all charges incurred 
during the process of organ donation, ensuring that donor families are not billed for any of them. 
Once contacted, the local OPO will send a procurement coordinator to the referring hospital. These 
coordinators perform a number of administrative and technical functions. covering every aspect of the 
donation process. Upon receiving a referral they will perform an evaluation and discuss organ 
donation,with the potential donor's family, making sure the relatives have a complete and satisfactory 
t!xplanation of the diagnosis of brain death and a clear understanding of the organ procurement 
process. Families should be informed as soon as possible after the irreversibility of the It!thal brain 
damage has been established, and given a clear explanation of the prognosis. This will give them time 
to al:l:ept the patient's death. and allow them to deal with their grief. It is extremely important to 
respel:t th is phase, as it has been demonstrated that consent for donation increases from 18 % to 60 % if 
the family is allowed to deal with the concept of brain death tirst, and the issue of organ donation is 
hrought up at a later time3. Religious beliefs about human life, the body, and life after death are 
t!xtremely important considerations for those involved in organ donation and transplantation. No major 
religion specitically prohibits organ donation, although in some situations there may be restrictions. 
Tahle I summarizes some of the major religious and cultural beliefs associated with organ donation and 
transplantation21 . Families may feel the need to discuss the matter with a church representative before 
making a ut!cision. 
If the family decides to donate. a "l:l)llSent for donation" form is supplied hy the hospital or hy 
the procurement coordinator, and is completed and signed by the next-of-kin. In addition, the 
coordinator sees to it that all medicolegal requirements are met, from adequate documentation of brain 
death in the chart to securing permission from the coroner when necessary. Medical staff privileges for 
the recovery teams are also arranged. Hospitals differ in their policies for granting such privileges. 
Some hospitals do not consider the organ procurement as a surgical procedure, because a determination 
of brain death has been made. In this circumstance, temporary privileges are not required for outside 
surgeons. 
At the same time the procurement coordinator assumes control of three main activities: I) 
donor evaluation, 2) coordination of donor and recipient matching; 3) donor operation and organ 
preservation and shipment to the recipient's hospitals. The role of the coordinator in each of these is 
critical. because the most important issue in organ procurement. once the decision to proceed has been 
made. is to have someone who "directs traffic," maintaining clear lines of communication between the 
members of the different teams involved. A lack of communication at this point can disrupt donor care 
and compromise organ stability. Therefore, the needs and protocols of the individual teams should be 
discussed in detail before any donor surgery is begun. In addition, if at all possible, the logistic 
arrangements between teams should be expedited so that no time constraints are placed on the host 
team. On the other hand, the host team must be tolerant, because extra-renal organs often have to be 
nown to distant parts of the country, and some recipient surgery may be quite complex and time 
consuming. To facilitate matters the host team should make available basic information on the donor, 
to expedite the evaluation by the visiting teams (Table II). 
DONOR EVALUATION AND MANAGEMENT 
There are very few absolute contraindications to organ donation. and they can be grouped into 
three hroad categories: 1) severe trauma. 2) malignancy outside of the Central Nervous System (CNS), 
and 3) active infections. The tirst category, that of trauma. refers only to injury to the organ itself. 
and will not preclude donation of those organs that are not affected. Malignancy, other than primary 
eNS tumors. will also disqualify the prospective donor. An important group of exclusionary criteria is 
the presence of active infections. Systemic sepsis, active tuberculosis. viral t!ncephaJitis and Guillain-
Barre syndrome are contraindications to organ donation, as wt!ll as active ht!patitis. or the presence of 
the hepatitis B surface antigen. Past infection with hepatitis B virus, as evidenced by the presence of 
antibodies, does not preclude donation. Whether organs should be used if the donor has hepatitis C 
antibodies has been the subject of controversy in the last few years. There is evidence in the literature 
for HCV transmission after transplantation22 . However, the donor shortage is so serious at this time 
that HCV positive donors need to be considered, at least for life-saving organs like liver, heart and 
lungs23 . Policies concerning other organs, like kidney and pancreas, are currently being debated22,24. 
The human immunodeficiency virus (HIV) has had a great impact on the field of 
transplantation, and donors who test positive for HIV antibody are rejected. Prospective donors should 
also have a Venereal Oisease Research Laboratory test (VORL), as well as cytomegalovirus (CMV) 
titers. determined as soon as possible. The significance of a positive VORL is difficult to ascertain. 
hut it is our practice to treat recipients of VORL-positive donors with a course of benzathine penicillin. 
The CMV status of the donor has prognostic significance regarding the incidence, and severity, of 
subsequent CMV infections. Recipients of organs harvested from seronegative donors have a lesser 
chance of developing a CMV infection, regardless of their own serologic status25-27 . Epstein-Barr 
(EBV) and Varicella Zoster virus (VZV) are not part of the usual viral screening. The only situation 
where these viruses become relevant is when the donor has active disease related to them (infectious 
mononucleosis or systemic VZV infection). If this is the case organ donation should not be considered. 
Donors with infections under control, or those affecting organs not specitically considered for 
donation (i.e., an abdominal organ donor suffering from pneumonia) may still be suitable. Children 
who die due to bacterial meningitis related to Hemophilus intluenzae or Neisseria meningitidis can still 
he considered for donation. if the organism and its sensitivity are known beforehand. 
Prolonged organ ischemia related to severe hypotension or cardiac arrest might represent a 
contraindication to donation. However. it is the policy of the Pittsburgh Transplantation Institute to 
critically evaluate all donors. including those with cardia.c arrest and prolonged CPR. In fact. many of 
these donors have been found acceptable by post-CPR physiological and biochemical criteria. and their 
organs have been successfully transplanted 18.28,29. 
Other patients that may not be acceptable as donors are those with a long-standing history of 
diaoetes mt!llitus. hypertension. cardiac or peripheral vascular disease. But, again. the donor and 
\)rgan viability assessments should be carried out on a case by case oasis. and a patient not acceptable 
as a heart or lung donor might still he an excellent abdominal organ donor. Sometimes the suitability 
of individual organs can be assessed only after direct examination by the donor surgeon, at the time of 
procurement. 
The donor age deserves special mention. The chronological age is less important than the 
physiologic age, when assessing for specific organ donation. For some organs age may not be an 
important limiting factor30. The liver is, in a certain way, protected from aging, and we have 
successfully used livers from donors as old as 75 years. Popper, in 1985, dedicated an extensive 
review to the aging of the I iver31. According to his study, the organ's great functional reserve, its 
regenerative capacity, and its large blood supply are the key factors in delaying aging in the liver, as 
compared to other organs. Table III shows the age guidelines for individual organs used in our 
institution. In general it is rare to tind a suitable heart or lung allograft from donors over the age of 60 
due to the increased incidence of coronary artery disease and chronic pulmonary disease. 
In summary, given the enormous need for organs and the very few criteria that absolutely 
disqualify a potential donor, the local OPO should be contacted in virtually every case. Table II shows 
the data collection form used by the Center for Organ Recovery and Education (CORE: the Western 
Pennsylvania. Southern New York and West Virginia organ procurement agency). These data should 
be promptly faxed to those involved in the evaluation process. 
Individual Organ Alisessment: Abdominal Organs 
The criteria used to determine the suitability of kidneys are very tlexible. As shown in Table 
III. a kidney donor can be between 1 month and 75 years of age. Serum creatinine and blood urea 
nitrogen (BUN) are used as markers of donor renal function. and should be normal. Obviously, donors 
with chronic renal disease are not considered for kidney donation. However, patients with transient 
creatinine and BUN elevations. related to dehydration and/or hypotension, are not excluded from 
kidney donation if the BUN and creatinine fall after appropriate volume correction. 
Attempts at predicting liver allograft function following transplantation. based upon donor 
intiJrmation. have met with little success. The diverse literature23•32-43 devoted to the topic is 
testimony to our lack of a clear understanding, one that can translate into well-informed decision 
making during donor evaluation. As a rule. the donor should have normal or near-normal serum 
aspartate aminotransferase (AST), serum alanine aminotransferase (AL T), bilirubin, and prothrombin 
time. but we have successfully used livers from donors with AST and AL T that were 10 times over 
the upper limit of normal. The important parameter is not an isolated AST and/or ALT value, but the 
trend established since the leu admission44. The bilirubin can be elevated due to massive blood 
transfusions used during the resuscitation of a shocked patient. A history of hepatitis or alcoholism is 
certainly a warning sign, but does not preclude the use of the liver. In general, in the case of a 
marginal liver donor, the intraoperative assessment by the donor surgeon is the best single piece of 
information. 
There is only one absolute exclusion criterion in the evaluation of a pancreas donor. and that is 
a history of diabetes mellitus. Amylase elevations have been seen in as many as 39% of pancreas 
donors. without any evidence of pancreatitis. and thus isolated hyperamylasemia does not 
contraindicate the use of the pancreas45. The serum glucose may be falsely elevated in donors 
receiving steroid therapy, or as a result of decreased circulating insulin46. 
Intestinal transplantation is emerging as a valuable modality for the treatment of patients with 
intestinal failure. Early in 1993 UNOS formed a subcommittee responsible for systematizing the 
listing of recipients, help identify suitable donors, and establish guidelines for the equitable allocation 
of intestinal grafts, both at the local and national levels. Because of the time constraints. it is 
impossible to perform a functional assessment of the donor bowel. Relatively young age, hemodynamic 
stability, and donor-recipient size match are the critical parameters used in evaluating an intestinal 
donor-+ 7. At our institution. preference was initiall y given to infant and juvenile donors with stable 
hemodynamics. However, the age range has been gradually expanded, provided the donor is stable and 
receiving minimal vasopressor support (...::;. 10 ug/kg/min of dopamine). Size matching is always given 
special consideration. The majority of intestinal transplant recipients have undergone extensive 
intestinal resections, leading to a signiticant reduction in the size of the abdominal cavity. Therefore, 
donors are chosen that are 15% to 40% smaller in body weight than the selected recipients47. 
Individual Organ Assessment: Thoracic Organs 
Besides a negative history of cardiac disease and a normal chest x-ray the donor should have a 
normal heart physical exam and 12-lead electrocardiogram. However, a number of electrocardiographic 
changes might be detected in brain dead patients, which do not preclude thoracic organ donation48,49. 
A brain dead patient able to maintain a systolic blood pressure greater than 90mm Hg with a dopamine 
requirement less than 10 ug/kg/min is considered a suitable candidate for heart donation50,51. Cardiac 
isoenzymes are recommended in case of chest trauma, to rule out myocardial contusion, and when the 
potential donor has suffered a cardiac arrest or prolonged hypotension. Clearly, in male donors over 
the age of 35, the incidence of coronary artery disease increases, especially in the face of risk factors 
such as hypercholesterolemia, family history and a history of smoking. Coronary angiography may be 
helpful in the evaluation of high risk and older donors, but it is not routinely required, and most 
hospitals will find the logistics of performing it prohibitive. Therefore, a decision will have to be made 
hased on a cardiologic consultation. evaluating the history, electrocardiogram, and echocardiogram. 
As is the case for the liver, and due to the severe shortage, it is prudent even in high risk donors to 
have the heart examined on the table following sternotomy. Visualizing and palpating the coronary 
arteries will give a signiticant amount of information with respect to the incidence of coronary artery 
disease. If plaques are felt along the left main coronary artery or left anterior descending artery, the 
heart. in most cases, will not be suitable for transplantation. In extreme cases of a very sick recipient. 
however, the transplant team may make a decision to take this heart, and isolated cases of coronary 
artery hypass being performed at the time of transplantation have been reported. Indeed, reports exist 
stating that in cases of isolated mild coronary artery disease. the donor allograft functions well with no 
increase in early mortality. 
Transesophageal echocardiography has recently been demonstrated to he an important adjuvant 
in the evaluation of a potential cardiac donor. Severe cardiac hypertrophy, valvular defects and global 
myocardial dysfunction or segmental wall abnormalities have been diagnosed in what appeared to be 
()therwise reasonable cardiac donors. At this time. limited information is available about the use of 
such hearts. and in most cases it will be prudent to avoid the use of a heart with demonstrated wall 
motion ahnormalities52. In general. minor changes in the electrocardiogram or echocardiogram. 
localized infection53 • transitory hypotension, brief cardiac arrest and thoracic trauma. do not 
contraindicate heart donation. The importance of donor-recipient weight mismatch over 20% is critical 
(lnly in the face of high pulmonary vascular resistance. In carefully sdected donors. survival following 
transplantation with a donor hetween 40-55 years of age is no different than that ohserved in the case 
of younger donors54. As the limits for donor selection are extended. evidence hecomes more clear 
that it is safe to extend donor age up to 55-60, and ischemic time farther than four to five hours55-57. 
The presence or absence of cardiac or cardiopulmonary arrest in of itself is not a 
contraindication to the use of a heart for transplantation. Especially in the pediatric population, it has 
been found that even in donors who have undergone extended cardiopulmonary resuscitation (up to 125 
minutes) as long as cardiac function at the time of cardiectomy is normal, there does not appear to be 
an increased risk for performance of the heart or survival following transplantation. 
All of the selection criteria mentioned in the case of a heart donor also apply to heart-lung or 
isolated single or double lung donors. In addition, a donor is not acceptable for lung or heart-lung 
donation when there is a history of heavy smoking, chronic lung disease, or pulmonary aspiration. 
The height. weight and chest circumference of the heart-lung donor should closely match those of the 
recipient. A number of physiological parameters can be used when assessing a lung donor, including 
the Pa02/FI02 ratio <2. 250 torr) and peak airway pressure ( < 30 cm H20 with 15 ml/kg of tidal 
volume and 5 cm H20 of PEEP) 58-60. Aspiration pneumonia is frequent in the brain dead patient, 
and thus the character of the sputum is a critical piece of information. The role of bronchoscopy is 
still being debated, considered mandatory by some authors61 , while others feel it is indicated only 
when there is a question of foreign-body aspiration, or to obtain sputum for Gram stain and culture46. 
Bronchoscopy will provide, however, important culture information to guide appropriate antibiotic 
therapy following transplantation. In cases where frank purulence is noted on bronchoscopy, the lungs 
will not be suitable. However, it is conceivable that one lung may be salvaged for transplantation from 
a set where one appears to be more infected than the other. 
COORDINATION OF DONOR AND RECIPIENT MATCHING 
• Once the coordinator tinishes the donor evaluation there are still many hours of intense work 
het(}fe completing the process. After obtaining the appropriate consent, therapeutic efforts should be 
geared to protect the donated organs. until the actual retrieval can be carried out. Their integrity 
should be maintained by optimal organ perfusion, avoidance of further damage, and their subsequent 
r~moval and preservation with minimal ischemic injury. Care of the donor during organ procurement. 
therefore. requires a continuation of the intensive care that was provided before brain death was 
declared, followed by a precise surgical procurement procedure. While in the '70s and early '80s 
donor management mainly, if not exclusively, addressed kidney function, nowadays the patient must 
always be approached as a multiorgan donor, and this can present a real challenge to the physician 
managing the case. He or she should keep the patient hemodynamically stable, with optimal organ 
perfusion and oxygenation. This is not easy because of the loss of many body reflexes, and the 
dramatic changes in the hormonal milieu62 . Several studies have shown a significant reduction of 
cortisol63 , insulin63 , and thyroid hormones48,63-67. Also, 50-70% of brain-dead patients suffer from 
diabetes insipidusSU~9K A number of protocols that call for the use of hormones like triiodothyronine, 
cortisol, or insulin during donor management46,49,64,66,67,70 have given contlicting results. The 
details of donor management are provided in Chapter 2 (Section XV), and will not be repeated here. 
We will only stress a few points we believe to be important. Adequate perfusion should always be 
maintained. while keeping the use of vasoactive drugs to a minimum. This may require the 
administration of several liters of t1uid, to obtain adequate tilling pressures. Replacement therapy with 
fresh frozen plasma, platelets, and cryoprecipitate may be used if a serious bleeding diathesis is 
present. However, even if fibrinolysis is suspected, epsilon aminocaproic acid should be avoided 
because it can induce microvascular thrombosis in the donor organs. 
During this phase the procurement coordinator asks local transplant programs about their needs 
for organs. Under the current system local programs have tirst priority, and only when organs are not 
used locally are inquiries made at the regional and national levels. An exception to this rule is when a 
prospective kidney recipient. who resides in another region, is found to have a so-called "six antigen 
match." These kidneys have to be St!nt away, with the receiving transplant center "paying back" at a 
later date. Organ allocation is a very complicated and controversial subject, and what system should be 
used is presently being debated 10. As of this writing, amendments to the National Organ Transplant 
Act are being discussed in the Congress, and it is not clear what changes will he implemented. A 
point system for renal transplantation was developed in Pittsburgh in 1985, that gave credit points to 
renal transplant candidates. Credits were acquired for time waiting, quality of antigen match, degree 
of immunologic sensitization. medical urgency, and logistical considerations of getting the donor organ 
and the recipient together within the time limitations of safe organ preservation. The system went in 
dfect in western Pennsylvania on January I. 19869. Although initially adopted by UNOS on 
November I. 1987. the point system never went into effect at the national level due to difticulties 
encountered in reconciling it to a myriad of local interests. A similar point system was developed for 
I iver transplantation, having been in place at Pittsburgh since January, 1987. Our experience with 
organ allocation based upon point systems, where organs go to those who have been waiting longer or 
are sicker, has been most favorable. Graft and patient survivals have not suffered by giving organs to 
sicker or older patients. At the same time, our observations provide some assurance that the concepts 
of equitable access and efficient use of a scarce societal resource are not mutually exclusive. 
HLA matching is not a critical issue for extrarenal organs. However, we routinely perform 
HLA typing on all extra-renal organs, a practice that is at variance with what most other institutions do 
in this country. Although it is expensive, we consider it important because it allows us to determine the 
presence of microchimerism in the recipient, information that may be extremely useful in the future, 
when deciding how to manage the immunosuppression 71. 
Whenever the recipients for all the abdominal and thoracic organs are identified. an operating 
room time in the donor hospital is arranged. The procurement coordinator contacts the recipient 
institutions to arrange for the simultaneous arrival of all the harvesting teams. Kidneys have been 
harvested by local teams for many years, and shipped if not used locally. Today, a similar practice is 
being adopted in the United States for other organs, particularly livers72. 
The intestinal donor should receive intravenous ampicillin and cefotaxime. at the appropriate 
doses. when tirst evaluated, and every 6 hours after that. The last dose is given in the operating room 
at the time of harvesting. Also, poly-ethyleneglycol-electrolyte solution Edolytely~F is administered 
through the naso-gastric tube to t1ush the intestine. The total amount ranges from 250-2.000 mi. 
depending on the recipient's body size (250 ml in the infant - 2.000 ml in the adult) and the 
administration rate is 10-30 ml/min. After the intestinal t1ushing, an antibiotic mixture that includes 
polymixim E (100 mg), tobramycin (80 mg), and amphotericin B (500 mg) is given through the naso-
gastric tube every 4 hours, until harvesting. In pediatric donors the doses are halved. while infants 
receive only one fourth of the dose. Newborns receive no intestinal preparation. If pre-harvest t1ushing 
cannot be performed this is done after procurement, using cold Ringer's lactate. Also. polymixin B or 
kanamycin can be substituted for polymixin E, if the latter is not available at the donor hospital. 
MULTIORGAN DONOR OPERATION 
Ant'S I ht'Siu 
The donor operation can be time consuming and the role of the anesthesiologist is very 
important, especially if we compare the multiple organ procurement that is now usually performed with 
those carried out in the past, when the kidneys were often the only organs harvested. A complete 
review of the anesthetic aspects of organ donation was recently published73 , and we will restrict 
ourselves to its salient points. 
The goal of medical management during organ procurement is to avoid ischemic organ damage 
by optimizing organ perfusion. Therefore, care of the donor is a continuation of the intensive care that 
was provided before brain death (see Chapter 2, Section XV). The most important issue is the clear 
communication between the members of the procurement team because the surgical procedure and 
procurement protocol may differ depending on the procurement team and the specitic organ. For the 
preoperative evaluation of the donor the anesthesiologist should review the medical and surgical 
histories. including the cause of brain death. condition and supportive measures of vital organs. drug 
allergies. and medications. Cardiopulmonary function is assessed by means of the hemodynamic 
protile, requirement of inotropic support, efticiency of gas exchange, degree of ventilatory support. 
chest X-ray, electrocardiogram. arterial blood gas tensions and acid-base state. Renal function is 
evaluated by urine output. blood urea nitrogen. and serum levels of creatinine and electrolytes. 
Hepatic function is evaluated by AST, ALT, and bilirubin. and pancreatic function by blood glucose 
level and serum amylase. Hemoglobin concentration and the blood type of the donor are identitied to 
prepare blood products. In addition, the validity of hrain death certitication. consent from family 
members. and permission from the coroner are veri tied. The transition from the ICU to the operating 
room (OR) is a crucial period and the donor is continuously monitored. vt!ntilated. and treated. 
Intraoperative care of the donor is essentially similar to that of other critically ill patients 
undergoing major surgery, although management of pathophysiologic changes unique to the donor 
should be clearly understood. In general. equipment and medications routinely available for general 
anesthesia are satisfactory for the management of donors. However. a volume ventilator may be 
needed for donors requiring high levels of PEEP or airway pressure. The operating room should be 
kept warm. and a warming blanket and blood warmer are necessary to prevent hypothermia. A large 
volume of crystalloids and colloid solutions (e.g., 5% albumin. plasma protdn fraction. or hetastarch) 
Jnd tive units of packed red blood cells should be prepared. The electrocardiogram is monitored. 
rreierably using lead V5. to detect arrhythmias or myocardial ischemia. particularly in heart donors. 
Blood pressure is monitored by an indwell ing catheter in the radial artery or brachial artery. The 
femoral artery cannulation is avoided because the aorta will be cross-clamped. Central venous pressure 
(CVP) monitoring is essential74, and a pulmonary arterial (PA) catheter is useful in unstable donors. 
Two-dimensional transesophageal echocardiography may be used to assess preload and cardiac 
contractility in unstable hean donors. Urine output and body temperature are monitored, and all or 
some of the following laboratory tests may be needed: hemoglobin and hematocrit, arterial blood gas 
tensions and acid-base state, serum electrolytes, ionized calcium, lactate, and blood glucose level. 
General anesthetics are required to blunt sympathetic response that occurs during surgery 75. 
This so-called "mass reflex" is caused by neurogenic vasoconstriction and stimulation of the adrenal 
medulla by the spinal retlex are, and manifests as tachycardia hypertension, perspiration, and 
involuntary movements. These movements, also known as "Lazarus sign" (that includes arm and hand 
movements towards the body) can be very disturbing to those involved in the organ recovery, and 
muscle relaxants should be administered ahead of time. 
lsotlurane is the agent of choice because the degree of myocardial depression is less than with other 
inhalation agents. Halothane is avoided in liver donors because hepatotoxicity may be a concern in the 
presence of potential hepatic ischemia. Entlurane is avoided in kidney donors because it increases the 
blood level of inorganic fluoride. Short-acting narcotics such as fentanyl (5-10 ug/kg) may be used in 
hemodynamically unstable donors. In addition, muscle relaxants (pancuronium bromide (0.05 to 0.1 
mg/kg) or vecuronium bromide (0.05 to 0.1 mg/kg)] are required to provide satisfactory abdominal 
muscle relaxation and to abolish involuntary movements. Other pharmacological interventions include 
systemic heparinization (300-500 units/kg) before cannulation of the aorta, mannitol (0.25 to 0.5 g/kg) 
and furosemide (40 mg) to induce diuresis before division of the renal pedicle. and prevent ischemia-
induced acute tubular necrosis 76-78. Alpha-adrenergic receptor blockers. such as phenoxybenzamine 
hydrochloride, may be used to promote renal vasodilation and prevent vasospasm 79. However, these 
hlockers are not recommended in multiple-organ procurement because their effects on other organs are 
unknown. Prophylactic administration of antibiotics such as broad-spectrum cephalosporins is 
recommended by some centers80-81 , although its efficacy is controversial44.82 . 
Specitic goals of ventilatory care are to maintain a Pa02 between 70 and 100 mmHg, an 
llxygen saturation of arterial hemoglobin (Sa02) greater than 95%, and a PaCO:! within the range of 
35 to 45 mmHg, to avoid pulmonary complications. In hypothermil.: donors. a mild respiratory 
alkalosis (pH 7.4 to 7.5) may be preferred to improve tissue perfusion83 ,84. This goal frequently is 
achieved by ventilating with a tidal volume of 10 to 15 ml/kg, a respiratory rate of fewer than 20 
breaths per minute, cf~ of 30% to 40%, and a low level of PEEP « 5 cmH20). However, when 
pulmonary complications interfere with gas exchange the tidal volume is increased up to 20 ml/kg, the 
respiratory rate up to 20 breaths per minute, and the PEEP up to 10 cmH20. In general, an increase 
in ci~ is preferred to an excessive tidal volume and high PEEP, to maintain venous return and 
splanchnic blood flow. 
The goal of circulatory care is to preserve perfusion of all organs that are to be procured by 
maintaining systolic blood pressure between 100 and 120 mmHg, with a CVP less than 10 cmH20 and 
minimal vasopressor support48,85,86. Hypotension (systolic blood pressure < 80 mmHg or mean 
arterial pressure < 40 mmHg) is associated with an increased incidence of acute tubular necrosis and 
nonfunction of the donor kidneys87 ,88, as well as poor function of the liver89. However, maintaining 
a satisfactory blood pressure is difficult to achieve at times because of altered circulatory physiology in 
the brain dead donors. Preload frequently is decreased because of blood loss, vasomotor paralysis, 
lliuretic therapy, or diabetes insipidus. Tachycardia. bradycardia, and arrhythmias caused by massive 
sympathetic discharge are not unusual, and myocardial contractility frequently is impaired by 
myocytolysis, coronary spasm, and reduction of myocardial energy storage90. Afterload may be 
increased by excessive sympathetic tone or decreased by vasomotor paralysis. 
Intravascular volume is adjusted with the guidance of the CVP « 10 cmH20). Fluid deticit 
is corrected with the infusion of a balanced electrolyte solution (e.g., lactated Ringer's) or a colloid 
solution (5 % albumin or hetastarch)91. Urine output and insensible losses are replaced by a hypotonic 
solution with glucose (e.g., 5% dextrose in 0.45% NaCl. 1 mllkg per hour). Adjustment of 
intravascular volume may decrease the need for vasopressors in many cases92 , but acute volume 
expansion may increase myocardial oxygen consumption, congestive heart failure. arrhythmias. and the 
need for inotropic support, because the compliance of the heart is decreased in most donors88. 
Excessive urine output (> 200 to 250 ml per hour) is replaced by a hypotonic electrolyte solution with 
supplementation of potassium chloride (KCl, 20 mmoI/L). When hypotension persists even after 
adequate volume replacement. vasopressors may be required. Dopamine hydrochloride (2 to 5 
ug/kg/min and up to 10 ug/kg/min) is the first choice to improve cardiac contractility. Other inotropes 
incluoe oohutamine hydrochloride (2 to 10 ug/kg/min) and isoproterenol hydrochloride (0.1 to I 
ug/kg/min), hut these drugs may dilate peripheral vascular heds decreasing hlooo pressure. Alpha-
vasopressors (phenylephrine hydrochloride, norepinephrine bitartrate, or metaraminol bitartrate) are 
avoided because they may decrease splanchnic and coronary blood flow93 ,94. In addition. the oxygen-
carrying capacity to the peripheral tissues is improved by transfusion of packed red blood cells (1 to 3 
U) to maintain the hematocrit between 25 % and 30 % 95 . 
Severe cases of tachycardia and hypertension caused by the mass reflex may be controlled by 
the administration of general anesthetics, a beta-antagonist, such as labetalol hydrochloride or esmolol 
hydrochloride, or a calcium channel blocker, such as verapamil hydrochloride63 . Occasionally, an 
alpha-blocker such as hydralazine or sodium nitroprusside may be given to reduce afterload. 
Supraventricular or ventricular arrhythmias are treated with conventional antiarrhythmic drugs. 
Circulatory arrest, which occurs in 10% of potential donors and in 66% of referred donors96, is 
treated according to conventional circulatory resuscitative measures, but if bradycardia is a concern. a 
direct-acting agent such as isoproterenol or epinephrine is used because donors are unresponsive to 
centrally-acting chronotropic drugs, such as atropine. 
Progressive hypothermia which is seen in up to 86% of donors because of the loss of brain 
stem function48 results in sinus bradycardia, atrioventricular dissociation, and ventricular arrhythmias. 
At a temperature lower than 280 C, prolonged PR and QT intervals and wide QRS complexes are 
replaced by T-wave inversion, ST-segment depression, and ventricular tibrillation. Other effects of 
hypothermia are a leftward shift in the hemoglobin-oxygen dissociation curve, an increase in blood 
viscosity, decrease in splanchnic blood flow and glomerular tiltration, hyperglycemia. and metabolic 
and respiratory acidosis. Body temperature is kept within the normal range (> 35°C) by increasing 
the room temperature, infusing all fluids through a blood warmer, and using a warming blanket and a 
heated humidifier in the inspiratory limb of the ventilation circuit. 
Adequate diuresis (> 0.5 mllkg per hour, preferably 1 to 1.5 mil kg per hour) is important 
hecause urine output is an indirect indication of preload and is a prognostic indicator for renal graft 
and hepatic function97 . The administration of fluid or dopamine may be effective in maintaining 
aJt!quate renal perfusion and diuresis. However, a high dose of dopamine (> 10 ug/kg/min) may lead 
to acute tubular necrosis and nonfunction of the renal graft87 . For persistent 01 iguria, furosemide (1-2 
mg/kg) and mannitol (0.5 g/kg) may be administered. Diabetes insipidUS. caused by a nonfunctioning 
pituitary gland. results in polyuria. hypovolemia. and electrolyte imbalance. Excessive urine output is 
ft!placed with a hypotonic solution (0.45% NaCi with KCI 20 mmollL), and supplemental antidiuretic 
hormone is administered to maintain urine output in the range of 100 to 250 ml per hour. The 
synthetic analogue of vasopressin, desmopressin acetate (DDAVP), is preferred (0.5-1 U per hour) 
because of its long duration of action and a low pressor/antidiuretic effect rati09S . However, the 
pressor activity in excessive doses of DDA VP may increase the risk of acute tubular necrosis99 and 
reduce hepatic blood tlow 1OO. DDAVP increases the sensitivity to catecholamines lOO and 
catecholamine doses should be reduced when DDAVP is given to the donor. Hyperglycemia is a 
complication of diabetes insipidus and is treated by an infusion of insulin (5 to 10 U). 
Metabolic acidosis caused by inadequate tissue perfusion may be compounded by respiratory 
acidosis. Because of potential myocardial depression, metabolic acidosis is corrected by administration 
of sodium bicarbonate. When hypernatremia is a concern, tromethamine (tris-
[hydroxymethyl]aminomethane. THAM) may be used (0.3 molar THAM [mil = oody weight [kg] x 
hase ddicit [mmol/LJ) instead of sodium bicarbonate. Electrolyte imbalances (hypernatremia, 
hypokalemia. hypocalcemia, hypophosphatemia, and hypomagnesemia) caused by tluid shifts and 
diabetes insipidus may result in arrhythmias and myocardial dysfunction. Hypernatremia and 
hypokalemia are treated by administration of a hyponatremic solution (0.45% NaCl) and KCl (20 
mmollL). Ionized hypocalcemia caused by large blood transfusions is corrected by the administration 
of calcium chloride or calcium gluconate to preserve cardiac contractility. Hypomagnesemia is treated 
with magnesium sulfate (50 mg/kg), also to preserve myocardial contractility 101. Glucose metabolism 
is rdatively well maintained, although hyperglycemia may occur as the result of a decreased level of 
insulin and as a complication of diabetes insipidus. Serum levels of triiodothyronine. insulin. and 
cortisol are low in animal models. and the administration of triiodothyronine improve hemodynamic 
staoility oy maintaining myocardial stores of energy and glycogen. However. the oeneticial role of 
triiodothyronine is unclear in clinical settings49.65 . 
Coagulopathy may occur in organ donors. Dilutional coagulopathy is caused by the shift of 
intravascular volume, consumption coagulopathy may result from the release of tissue thromboplastin 
from injured tissues and the ischemic organs. and fibrinolysis results from intravascular coagulation or 
the release of tissue plasminogen activator from the ischemic tissues. Disseminated intravascular 
coagulation (DIC) has been reported in 80% of donors with head injury 102. out its clinical signiticance 
is unknown. Coagulation abnormalities are treated conservatively. 
Once cardioplegia is induced. no further supportive care is necessary. A fter cross-clamping of 
the aorta (the time is recorded by the procurement coordinator - see Table IV - ) mechanical ventilation 
and monitoring are discontinued, and all cannulas are removed. The organs are swiftly removed in the 
following sequence: heart, lungs, liver, pancreas, intestine, and kidneys. No supportive care is needed 
for procurement of the corneas or bones because these tissues tolerate a prolonged ischemia without 
significant injury. 
Donor operation 
Before starting a multiorgan procurement it is mandatory that the different surgical teams 
discuss the techniques and sequence they want to adopt. A detailed discussion of the surgical 
procedure is critical because. after aortic cross-clamping, time is of the essence. Everything should 
proceed as smoothly and expeditiously as possible, to minimize organ damage. The basic principle of 
any donor operation is the core cooling of the organs to be removed. Cooling of a solid organ at the 
time of donor circulatory arrest was described for experimental liver transplantation 33 years ago 103. 
It was then promptly applied to kidney preservation in clinical transplantation 104, and it still 
represents the single most important aspect of any organ preservation technique. The first solution 
used was chilled Ringer's lactate, replaced in the late 1960's hy the so-called Collins solution. 
characterized by an electrolyte composition close to the intracellular one 105 . This solution was 
successfully used for about 20 years, until the introduction of the University of Wisconsin 
solution 1 06,107, which extended the duration of organ viability. The easiest way to achieve almost 
immediate internal core cooling of the donor organs is hy in situ infusion of the preservation solution. 
chilled to 4llC, at the time of the circulatory arrest. The remaining technical aspects of organ retrieval 
are secondary to this critical maneuver. 
The surgical procedure for multiple cadaveric organ procurement underwent a progressive 
evolution. In 1984. when procurement of extrarenal organs was becoming more common, a technique 
was puhlished hy the Pittsburgh group 108, that required a meticulous in vivo dissection of the donor 
organs. and extensive manipulation of the ahdominal viscera. A subsequent retinement of this 
technique was introduced in 1986 109. This improved technique is the method in use today, and it is 
hasically characterized hy a "no-touch en-bloc removal" of the core cooled solid organs. The technical 
details of this operation lie outside the scope of this chapter. and we will only descrihe the major 
points. 
A complete midline incision is performed from the suprasternal notch to the pubis (Fig. 2). 
As soon as the thoracic and abdominal organs are visualized, the procurement coordinator collects the 
tirst information on the appearance of the donor organs, and relays it to the local OPO so that they can 
he made available to the recipient teams. The aorta is then exposed and encircled either immediately 
above or below the diaphragm (Fig. 3). The inferior mesenteric vein is encircled and cannulated for 
infusion of the cold portal perfusate. The aorta is then dissected for 2 cm at the level of the origin of 
the inferior mesenteric artery, which is tied and divided. The aorta is encircled at this level and 
prepared for cannulation. Figure 4 shows the donor inferior mesenteric vein and the infrarenal aorta 
cannulated for the cold perfusate. The common bile duct is tied distally, and transected close to the 
upper margin of the duodenum. and the gallbladder is incised and washed free of bile to prevent 
autolysis of the mucosa of the biliary tract. The arterial anatomy of the liver should be carefully 
examined for possible anomalies. Prior knowledge of any anomaly will be extremely helpful in 
preventing mistakes during organ removal. At this point the basic initial dissection is completed (see 
Figure 5), and the thoracic team prepare the chest organs for removal. The pleural spaces are opened 
widely after initial mediastinal dissection. Very little initial dissection is done around the inferior and 
superior vena cava and aorta other than to place sutures for the expected cannulation of the aorta for 
cardioplegia and/or the main pulmonary artery if the lungs are being harvested as well. The lungs are 
quickly examined through the pleural spaces and very little dissection is required thereafter. It should 
he noted that the donor's heart so far has continued beating spontaneously and maintained circulation 
()f all organs. 
As soon as the thoracic team completes their dissection. 300-500 units/kg of heparin are given 
IV. and the aorta is cannulated after ligating it distal to the inferior mesenteric artery (Fig. 4). The 
thoracic team then occludes the superior vena cava, and the aorta is simultaneously clamped proximal 
to the innominate artery and just above or below the diaphragm (Fig. 6). The cold infusion is started. 
the inferior vena cava is vented, and the heart is separately perfused with cold cardioplegic solution. 
The heart is removed tirst. If the lungs are heing harvested simultaneously, cold tlush is started 
through the pulmonary artery venting the solution through the left atrial appenuage. Once cardioplegia 
has been administered. the aorta is transected and the rest of the lung perfusion solution is allowed to 
Jrain through the open aorta. Mediastinal dissection is then carried out removing the lungs and heart 
en bloc if the block is to be used for a heart-lung transplant. The more common situation is one where 
the heart is harvested by one group and lungs are to be used for a separate transplant. In this situation. 
one the cardioplegia and lung perfusion has been completed, the heart is carefully dissected by the two 
teams ensuring that enough pulmonary artery and left atrial cuff remain on both the heart and the lungs 
making them both available for transplantation. Once the heart has been removed, the lung team can 
then proceed with extraction of the lungs. 
During this phase the abdominal organs are untouched, while they are exsanguinated and the 
cold perfusion is continued. Following the removal of the thoracic organs, the abdominal team 
proceeds with the final dissection and removal of the liver, pancreas, intestine, and kidneys. The 
technical steps have been outlined elsewhere by us47,108-111 and by others 1 12-1 14. After the organ 
harvest long segments of the il iac arteries and veins, inferior vena cava and aorta 115, (and carotid 
arteries in children) should always be removed and stored under hypothermic conditions. This ensures 
the ability to deal with all possible vascular problems that might be encountered during the recipient 
operations 115-119. 
With the development of the intestinal and multivisceral transplant program at the University 
of Pittsburgh (see Chapter 10, Section XV), a technique was developed for the removal of essentially 
the entire abdominal visceral bloc (Fig. 7)47. Anatomical considerations are fundamental during 
intestinal and multivisceral procurement, because recipients require different types of intestinal 
transplantation (isolated small bowel. liver and small bowel, true multivisceral. etc.) based on different 
pathology and needs. These procurement techniques do not interfere with that of other organs. In our 
tirst 35 intestinal donor operations there were 62 kidneys, 35 livers, 18 hearts and 3 lungs procured 
simultaneously47. 
At the end of the operation the procurement coordinator completes the ti.lrm shown in Table 
IV. These data are of critical importance for the recipient operations, and subsequent follow-up of the 
transplanted patients, which are the endpoint of a successful multiple organ procurement. 
LEGENDS 
FIGURE 1: Organ donor supply in the United States, 1980 through 1992 (from: Evans, RW, 
reference no. 5). 
FIGURE 2: Intraoperative photograph showing the total midline incision used for multiorgan 
procurement. (Courtesy of Andrei Stieber, M.D.). 
FIGURE 3: The aorta is dissected and encircled just above, or alternatively just below, the 
diaphragm. (Reprinted by permission from: Starzl TE et ai. "A flexible procedure for multiple 
cadaveric organ procurement, Surgery, Gynecology & Obstetrics, 158:223-230, 1984). 
FIGURE 4: Intraoperative photograph showing the donor inferior mesenteric vein (lMV) and the 
infrarenai aorta (IA) dissected and cannulated for the cold perfusion. (Courtesy of Andrei 
Stieber, MD). 
FIGURE 5: Liver hilar dissection, transection of the common bile duct and incision of the 
gallbladder fundus to prevent autolysis of the mucosa of the biliary tract. In this drawing the 
splenic vein is cannulated, but the inferior mesenteric vein can be cannulated alternatively, as 
shown in Figure 4. (Reprinted by permission from: Starzl TE, et ai. "A tlexible procedure for 
multiple cadaveric organ procurement, Surgery, Gynecology & Obstetrics, 158:223-230, 
1984). 
FIGURE 6: Occlusion of the superior vena cava intlow and simultaneous aortic clamping proximal 
to the innominate artery. The aorta is also simultaneously clamped just above or below the 
uiaphragm. Cardioplegic solution infused through the ascending aorta is allowed to run only in 
the hean. (Reprinted by permission from: Starzl TE, et al. .. A flexible procedure for multiple 
cadaveric organ procurement. Surgery, Gynecology & Obstetrics. 158:223-230, 1984). 
FIGURE 7: En-bloc harvesting of liver and small bowel from a pediatric donor. 
TABLE I: Major religious and cultural bt!liefs associated with organ donation anu transplantation. 
TABLE II: Donor data sheet used by the Western Pennsylvania Organ Procurement Organization. 
CORE (Center for Organ Recovery and Education). (Courtesy of Mr. Brian Broznick). 
TABLE III: Age guidelines for organ and tissue donation used at the Pittsburgh Transplantation 
Institute. 
TABLE IV: Intraoperative data collection sheet used by the Western Pennsylvania Organ 
Procurement Organization, CORE (Center for Organ Recovery and Education). (Courtesy of 
Mr. Brian Broznick). 
REFERENCES 
1. Data from United Network for Organ Sharing Research Department. UNOS Update 8:20-27, 
1992. 
2. Evans RW, Orians CE, Ascher NL: The potential supply of organ donors. JAMA 267:239-246, 
1992. 
3. Garrison RN, Bentley FR, Raque GH, Polk HC Jr, Sladek LC, Evanisko MJ, Lucas BA. There 
is an answer to the shortage of organ donors. Surg Gynecol Obstet 173 (5):391-396, 1991. 
4. UNOS Update. Vol 9. Issue 6. p.23. June 1993. 
5. Evans RW. Organ procurement expeditures and the role of tinancial incentives. JAMA 269:3113-
3118.1993. 
6. Orians CE, Evans RW, Ascher NL: Estimates of organ-specitic donor availability for the United 
States. Transplant Proc XXV(l): 1541-1542, 1993. 
7. Campbell JR, Layne JA: The donor dilemma: the lifelink foundation approach. UNOS Update 
Vol 9, issue 6, p. 16, lune 1993. 
8. Donation and Transplantation: Medical School Curriculum, UNOS (1992), Richmond. VA. 
9. Starzl TE, Shapiro R, Teperman L: The point system for organ distribution. Transplant Proc 
21 (Suppl.3):3432-3436. 1989. 
10. Starzl TE. Bronsther 0, Van Thiel D, Irish W, Abu-Elmagd K, Casavilla A: Prioritization and 
organ distribution for liver transplantation. Hepatology, in press. 
I\. Galletti PM: Bioartiticial organs. Journal of Artiticial Organs 16(1):55-60, 1992. 
12. Caplan A. Must be my brother's keeper? Ethical issues in the use of living donors as sources of 
liver and other solid organs. Transplant Proc. 25(2) 1997-2000. 1993. 
13. Kirchner SA. Living related lung transplantation. A new observation in single lung 
transplantation. AORN lournal 54(4):712-714. 1991. 
14. Xenotransplantation: The transplantation of organs and tissues hetween species. (Cooper DKC. 
Kemp E, Reemtsma K, White DJG, (eds), Sopringer-Verlag, Berlin, Heidelberg, 1991. 
15. Starzl TE, Fung J, Tzakis A, Todo S, Demetris AJ, Marino IR, Doyle H, Zeevi A, Warty V, 
Michaels M, Kusne S, Rudert W A, Trucco M: Baboon to human liver transplantation. 
Lancet 341 :65-71, 1993. 
16. Starzl TE, Tzakis A, Fung JJ, Todo S, Marino IR, Demetris AJ. Human liver xenotransplantation. 
Xeno. A Review of Xenotransplantation and Related Topics, in press. 
17. Marino IR, Tzakis AG, Fung JJ, Todo S, Doyle HR, Manez R, Starzl TE. Liver 
Xenotransplantation. In: Surgical Technology International, Braverman MH (ed.), A Medical 
Corporation Publishing, San Francisco California, in press. 
18. Anaise 0, Rapaport FF. Use of non-heart-beating cadaver donors in clinical organ transplantation 
logistics. ethics and legal consideration. Transplantation Proceedings 25(2):2153-2155. 1993. 
19. A detinition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical 
School to examine the definition of brain death. J AMA 1968; 205:337-340. 
20. Guidelines for the determination of death; report of the medical consultants on the diagnosis of 
death to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical 
and Behavioral Research. JAMA 1981; 246:2184-2186. 
21. Childress J: Attitudes of major western religious traditions towards uses of the human body and its 
rarts. In: D.A. Knight and PJ. Paris (eds), Justice and the Holy: Essays in Honor of Walter 
Harrelson. Atlanta. Scholar Press, 1989. 
22. Pereira BJG, Levey AS, Kirkman RL. Hepatitis C-positive individuals are not suitable for organ 
donation. Transplantation & Immunology Letter, 9(1):3-17. 1993. 
23. Pruim J. Klompmaker IDS]. Haagsma EB. Bijleveld CMA. Siooff MJH. Selection criteria for 
liver donation a review. Transplant Int 6:226-235. 1993. 
24. Roth D. Hepatitis C-positive individuals are suitable for organ donation. Transplantation & 
Immunology Letter. 9(1):2-6. 1993. 
25. Fox AS. Tolpin MD. Baker AL. Broelsch CEo Whittington PF. Jackson T. Thistleth waite JR. 
Stuart FP. Seropositivity in liver transplant recipients as a predictor of cytomegalovirus disease. J 
Infect Dis 157:383-385. 1988. 
26. Haagsma EB, Klompmaker U, Grond J. Herpes virus infection after orthotopic liver 
transplantation. Transplant Proc 19: 4054-4056, 1987. 
27. Rakela 1, Wiesner RH, Taswell HF, Hermans PE, Smith TF, Perkins 10, Keom RAF. Incidence 
of cytomegalovirus infection and its relationship to donor-recipient serologic status in liver 
transplantation. Transplant Proc 19:2399-2402, 1987. 
28. Yanaga K, Kakizoe S, Ikeda T, Podesta LG, Oemetris AG, Starzl TE: Procurement of liver 
allografts from non-heart beating donors. Transplant Proc 22:275-278, 1990. 
29. Yanaga K, Tzakis AG, Starzl TE: Personal experience with procurement of 131 liver allografts. 
Transplant International 2: 137-142, 1989. 
30. Teperman L, Podesta L, Mieles L, Starzl TE: The successful use of older donors for liver 
transplantation. lAMA 262:2837, 1989. 
31. Popper H. Aging and the liver. In Popper H. Levy GL (eds), Progress in liver diseases, vol VIII. 
Grune & Stratton, New York, pp 659-683, 1985. 
32. Kakizoe S, Yanaga K, Starzl TE, Oemetris AJ: Frozen section of liver biopsy for the evaluation 
of liver allografts. Transplant Proc 22:416-417, 1990. 
33. Kakizoe S, Yanaga K, Starzl TE, Oemetris AJ: Evaluation of protocol before transplantation and 
after reperfusion biopsies from human orthotopic liver allografts: Considerations of preservation 
Jnd early immunological injury. Hepatology 11:932-941, 1990. 
34. Adam R, Azouriay D, Astarciuglu I. Bao YM, Bonhomme L, Fredj G, Bismuth H. Reliability of 
the MEGX test in the selection of liver grafts. Transplant Proc 23:2470-2471, 1991. 
35. Bowers lL, Teramoto K, Clouse ME. 31 P NMR assessment of orthotopic liver transplant viability: 
the etfect of warm ischemia (abstract). 10th Annual Meeting of the Socity of Magnetic Resonance 
in Medicine. San Francisco, 663, 1991. 
36. Kanetsuna Y, Fujita S. Tojimbara T, FUl:hinoue S, Teraoka S. Ota K. Usefulness of 31P-MRS as 
J method of evaluating the viability of preserved and transplanted rat liver. Transplt Int. 5 (Suppl 
1): 5379-5381, 1992. 
37. Oellerich M, Burdelski M. Ringe B. Lamesch P, Gubernatis G, Bunzendahl H, Pichlmayr R, 
Herrmann H. Lignocaine metabolite tormation as a measure of pre-transplant liver function. 
Lancet 1 :640-642, 1989. 
38. Ozaki N, Gubematis G, Ringe B, Oellerich M, Wash ida M, Yamaoka Y, Ozawa K, Pichlmayr R. 
Arterial blood ketone body ratio as an indicator for viability of donor livers. Trans Proc 23:2487-
2489, 1991. 
39. Reding R, Feyaerts A, Wallemacq P, Lambotte L, Otte lB. Liver graft assessment in organ 
donors by the lidocaine monoethyglycinexylidide test is unreliable. Br. J. Surg. 79 (Suppl I): 
S 142, 1992. 
40. Sl:hroeder TJ, Gremse DA, Mansour ME, Theuerling AW, Brunson ME, Ryckman FC, Suchy FI, 
Penn I.Alexander JW, Pesce AJ, First MR. Balistreri WF: Lidocaine metabolism as an index of 
I iver function in hepatic transplant donors and recipients. Transplant Proc 21 :2299-2301, 1989. 
4\. Yamaoka Y, Taki Y, Gubernatis G, Nakatani T, Okamoto R, Yamamoto Y, Ishikawa Y, Ringe B. 
Bunzendahl H, Oellerich M, Kobayashi K, Ozawa K, Pichlmayr R.: Evaluation of the liver graft 
before procurement. Signiticance of arterial ketone body ratio in brain-dead patients. Transplt Int 
3:78-81, 1990. 
42. Burdelski M, Oellerich M, Raude E, Lamesch P, Ringe B. Raith H, Scheruhn M, Westphal C, 
Worm M, Bortfeld S, Sl:hultz M, Wittkind C, Hoyer P-F, Pichlmayer R. A novel approach to 
assessment of liver function in donors. Transplant Proc 1988; 20(1 )(Suppl.l) :591-593. 
43. Makowka L, Gordon RD, Todo S, Ohkohchi N. Marsh JW, Tzakis AG, Yokoi H, Ligush 1, 
Esquivel CO, Satake M. Iwatsuki S, Starzl TE: Analysis of donor aiteria for the prediction of 
outcome in clinical liver transplantation. Transplant Proc 19:2378-2382. 1987. 
44. StOl:k PG. Najarian JS. Ascher NL: Liver transplantation. In: Gallagher T1 and Shoemaker WC 
(eds.). Critical Care State of the Art. Fullerton, California. The Society of Critical Care Medicine. 
pp. 21-24. 1988. 
45. Hesse U1. Najarian JS. Sutherland DER: amylase al:tivity and pancreas transplants. Lancet 
2:(8457):726-728. 1985. 
~K Darhy 1M. Stein K. Grenvik A. Stuart SA: Approach to management of the heart heating brain 
dead organ donor. lAMA 261:2222-2228. 1989. 
47. Furukawa H. Casavilla A. Kadry Z. Nour B. Reyes 1. Ahu-Elmagd K. Tzakis A. Todo S. Starzl 
TE. Basic considerations for the procurement of intestinal grafts. Proceedings of the IIIrd 
International Symposium on Small Bowel Transplantation, Paris, November 3-6, 1993. 
48. Griepp RB, Stinson EB, Clark DA, Dong E, Shumway NE: The cardiac donor. Surg Gynecol 
Obstet 133:792-798, 1971. 
49. Novitzky D, Cooper DKC, Reichart B: Hemodynamic and metabolic responses to hormonal 
therapy in brain dead potential organ donors. Transplantation 43:852-854, 1987. 
50. Copeland JG, Emery RW, Levinson MM, Icenogle TB, Carrier M. Ott RA, Copeland lA, 
McAleer-Rhenman MJ, Nicholson SM: Selection of patients for cardiac transplantation. 
Circulation 75:2-9, 1987. 
51. Renlund DG. Bristow MR. Lee HR, O'Connell 18: Medical aspects of cardiac transplantation. J 
Cardiothorac Anesth 2:500-512. 1988. 
52. Stoddard MF and Logaker RA: The role of transesophageal echocardiography in cardiac donor 
screening. Am Heart 1 1993 lun; 125(6): 1676-81. 
53. Lammermeier DE, Sweeney MS. Haupt HE. Radovancevic B, Duncan 1M. Frazier OH: Use of 
potentially infected donor hearts for cardiac transplantation. Ann Thorac Surg 1990; 50:222-225. 
54. Luciani GB, Livi U. Faggian G. Mazzucco A: Clinical results of ht!art transplantation in 
recipients over 55. 1 Heart Lung Transplant 1992 Nov-Dt!c; 11 (6): 1177-83. 
55. Ptlugfelder PW, Singh NR. McKt!nzie FN, Menkis AH, Novick RJ. Kostuk WJ: Extending 
.:ardiac allograft ischemic time and donor age: t!ffect on survival and long-term cardiac function. 
1 Can.liovasc Surg (Torino) 1991 Jan-Ft!b;32(1):46-9. 
56. Menkis AH, Novick RJ. Kostuk Wl, Ptlugfelder PW, Powell AM. Thomson D, McKenzie FN: 
Successful use of the "unacct!ptable" heart donor. 1 Heart Lung Transplant 1991 Jan-Feb; 10(1 Pt 
1):28-32. 
57. Sweeney MS, Lammermeit!r DE. Frazier OH, Burnt!tt CM, Haupt eM. Duncan 1M: Extension of 
Jnnor criteria in cardiac transplantation: surgical risk vt!rsus supply-side t!conomics. Ann Thor 
Surg 1990; 50(1):7-10. 
58. Harjula A. Starnes VA, Oyer PE. Jamieson SW. Shumway NE: Propt!r donor selt!ction for heart-
lung transplantation. J Thorac Cardiovasc Surg 94:874-880. 1987. 
59. Tarazi RY, Bonser RS, Jamieson SW: Heart-lung transplantation. In: Gallagher TJ, ed, Critical 
Care State of the Art, Fullerton California Society of Critical Care Medicine; 1988, pp. 55-72. 
60. Todd RJ: Pulmonary transplantation. In: Gallagher TJ, ed, Critical Care State of the Art, 
Fullerton California Society of Critical Care Medicine; 1988, pp.41-53. 
61. Detterbeck FC, Mill MR, Williams W, Egan TM: Organ donation and the management of the 
multiple organ donor. Contemporary Surgery 42:281-285, 1993. 
62. Soifer BE, Gelb AW: The multiple organ donor: identification and management. Ann Intern 
Med 110:814-823, 1989. 
63. Novitzky D, Wicomb WN, Cooper DKC. Rose AG, Fraser RC, Barnard CN: 
Electrocardiographic. hemodynamic, and endocrine changes occurring during experimental brain 
death in the Chacma baboon. J Heart Transplant 4:63-69, 1984. 
64. Pennefather SH, Bullock RE: Triiodothyronine treatment in brain-dead multiorgan donors. A 
controlled study. Transplantation 55(6):1443,1993. 
65. Macoviak lA, McDougall IR. Bayer MF, Brown M, Tazelaar H, Stinson EB: Significance of 
thyroid dysfunction in human cardiac allograft procurement. Transplantation 43:824-826, 1987. 
66. Gifford RRM, Weaver AS, Burg IE, Romano PI, Demers LM, Pennock IL: Thyroid hormone 
levels in heart and kidney cadaver donors. J Heart Transplant 5:249-253, 1986. 
67. Wahlers T. Fieguth HG. Jurmann M. Cremer J, Coppola R. Schafers HJ. Beer C. Haverich A. 
Borst HG: Does hormone depletion of organ donors impair myocardial function after cardiac 
transplantation? Transplant Proc 20(Suppll ):792-794, 1988. 
68. Nygaard CEo Townsend RN. Diamond DL: Organ donor management and organ outcome: a six-
year review from a level I trauma center. J Trauma 30:728-732. 1990. 
69. BoJenham A. Park GR: Care of the multiple organ donor. Intensive Care MeJ 15:340-348. 
1989. 
70. Novitzky D. Cooper DKC. Morrell D. Isaacs $: Change from aerobic to anaerobic metabolism 
after brain death. and reversal following triiodothyronine therapy. Transplantation 45:32-36. 
1988. 
71. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, lldstad S, Ramos H, Todo S, Tzakis A, 
Fung jJ, Nalesnik M, Ruden W A, Kocova M: Cell migration and chimerism after whole organ 
transplantation: The basis of graft acceptance. Hepatology 17(6): 1127-1152, 1993. 
72. Miller CM, Teodorescu V, Harrington M, Harrington EB, Schwartz ME, Ambrosina G, Kadian 
M. Sampson J: Regional procurement and expon of hepatic allografts for transplantation. Mt 
Sinai J Med 57:93-96, 1990. 
73. Kang YG, Kormos RL, Casavilla A: Organ procurement from donors with brain death. In: Grande 
C (editor): Trauma Anesthesia and Critical Care. WB Saunders; Philadelphia 1993; 1013-24. 
74. Luksza AR: Brain-dead kidney donor: selection, care, and administration. Brit Med J 1:1316-1319, 
1979 
75. Wetzel RC, Setzer N. Stiff JL, Rogers MC: Hemodynamic responses in brain dead organ donor 
patients, Anesth Analg 64:125-128,1985 
76. Dahlager JL and Bilde T: The integrity of tubular cell function after preservation in Collin's 
solution. Canine kidneys, Transplantation 21 :365-369, 1976 
77. Rijksen JFWB: Preservation of canine kidneys. The etfect of various preservation tluids on renal 
morphology and function, Thesis, University of Leiden, Netherlands 
78. Schloerb PR, Postel J, Moniz ED, Dolginow YO: Hypothermic storage of the canine kidneys for 
48 hours in a low chloride solution, Surg Gynecol Obstet 141 :545-548, 1975 
79. Miller CH, Alexander JW. Smith El. Fidler JP: Salutary effect of phentolamine (Regitine) on renal 
vasoconstriction in donor kidneys: experimental and clinical studies, Transplantation 17:201-210. 
1974 
80. Ahramowicz M: The choice of antimicrobial drugs, Med Lett 24:21-23, 1982. 
81. Ahramowicz M: Choice of cephaiosporins, Med Lett 25:57-60. 1983 
82. Schuler S, Parnt R, Warnecke H. Matheis G, Hetzer R: Extendoo donor criteria fiJr heart 
transplantation. J Heart Transplant 7(5):326-330, 1988. 
83. Kroncke GM. Nichols RD. Mendenhall JT. Myerowitz PO: Ectothermic philosophy of acid-base 
halance to prevent fibrillation during hypothermia. Arch Surg 121 :303-304. 1986 
84. Swain lA: Hypothermia and blood pH: a review, Arch Intern Med 148:1643-1646, 1988. 
85. Flanigan WI, Ardon LF, Brewer TE, Caldwell FT: Etiology and diagnosis of early post-
transplantation oliguria, Am 1 Surg 132:808-815, 1976 
86. Toledo-Pereyra LH, Simmons RL, Olson LC, Najarian IS: Cadaver kidney transplantation effect 
of hypotension and donor pretreatment with methylprednisolone and phenoxybenzamine, Minn 
Med 62:159-161, 1979 
87. Whelchel 10, Oiethelm AG, Phillips MG, Ryder WR, Schein LG: The effect of high-dose 
dopamine in cadaver donor management on delayed graft function and graft survival following 
renal transplantation, Transplant Proc 18 :523-527, 1986 
88. Wicomb WN, Cooper DKC, Lanza, RP. Novitzky D, Isaacs S: The etfects of brain death and 24 
hours storage by hypothermic perfusion on donor heart function in the pig, 1 Thorac Cardiovasc 
Surg 91: 896-909. 1986 
89. Busuttil RW, Goldstein LI, Danovitch GM, Ament ME, Memsic LD: Liver transplantation today, 
Ann Intern Med 104:377-389, 1986 
90. Novitzky D, Rose AG, Cooper DKC: Injury of myocardial conduction tissue and coronary artery 
smooth muscle following brain death in the baboon, Transplantation 45 :964-966, 1988 
91. Davidson I, Berglin E. Brynger H: Perioperative tluid regimen. hlood and plasma volumes, and 
colloid changes in living-related donors. Transplant Proc 16: 18-19, 1984 
92. Kormos RL, Donato W. Hardesty RL, Griftith BP, Kiernam 1, Trento A: The intluence of donor 
organ stability and ischemia time on subsequent cardiac recipient survival, Transplant Proc 20:980-
983. 1988 
93. Siapak M: The immediate care of potential donors for cadaveric organ transplantation. Anaesthesia 
33:700-709, 1978 
94. Levinson MM and Copeland JG: The organ donor: physiology, maintenance. and procurement 
considerations, Contemp Anesth Pract 10:31-45, 1987 
95. Hardesty RL and Griftith BP: Multiple cadaveric organ procurement for transplantation with 
emphasis on the hean. Surg Clin North Am 66:451-457. 1986 
96. Emery RW, Cork RC, Levinson MM, Riley JE, Copeland J, McAleer MJ, Copeland JG: The 
cardiac donor: a six-year experience, Ann Thorac Surg 41 :356-362, 1986 
97. Lucas BA, Vaughn WK, Spees EK, Sanfilippo F: Identification of donor factors predisposing to 
high discard rates of cadaver kidneys and increased graft low within one year post transplantation. 
Transplantation 43:253-258, 1987 
98. Richardson DW and Robinson AG: Desmopressin, Ann Intern Med 103:228-239, 1985 
99. Schneider A, Toledo-Pereyra LH, Seichner WD, Zeichner WO, Allaben R, Whitten J: Effect of 
dopamine and pitressin on kidneys procured and harvested for transplantation, Transplantation 
36(1): llO-111, 1983 
100. Cowley A W, Monos E, Guyton AS: Interaction of vasopressin and the baroreceptor retlex system 
in the regulation of arterial blood pressure in the dog, Circ Res 34:505-514, 1974 
101. Davis S, Olichwier KK. Chakko SC: Reversible depression of myocardial performance in 
hypophosphatemia, Am J Med Sci 295:183-187, 1988 
102. Kaufman HH, Hui KS, Mattson JC, Borit A, Chilos TL, Hoots WK, Bernstein DP, Makela ME. 
Wagner KA, Kahan BO: Clinicopathologic correlations of disseminated intravascular coagulation 
in patients with severe head injury, Neurosurg 15:34-42, 1984 
103. Starzl TE. Kaupp HA Jr, Brock DR, Lazarus RE, Johnson RV: Reconstructive problems in canine 
liver homotransplantation with special reference to the postoperative role of hepatic venous tlow. 
SurgGynecolObstet 111:733-743.1960. 
104. Starzl TE: Experience In Renal TransnlantatiQn WB Saunders Company, Philadelphia. PA, 1964. 
105. Collins GM. Bravo-Shugarman M, Terasaki PI: Kidney preservation for transportation. Lancet 
1969; 2:1219-1222. 
106. Belzer FO, Southard JH. Principles of solid organ preservation by cold storage. Transplantation 
45:673-676, 1988. 
107. Todo S. Tzakis A. Starzl TE: Letter to the Editor: Preservation of livers with UW or Euro 
Collin's solution. Transplantation 46:925-926, 1988. 
108. Starzl TE, Hakala TR, Shaw BW Jr. Hardesty RL. Rosenthal TJ, Griffith 8P, Iwatsuki S, Bahnsan 
HT: A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet 
158:223-230, 1984. 
109. Starzl TE, Miller C, Broznick B, Makowka L: An improved technique for multiple organ 
harvesting. Surg Gynecol Obstet 165:343-348, 1987. 
110. Starzl TE, Miller CM and Rapaport FT: Organ procurement. In: Care of the Sur2ical Patient 
Section XI, Chapter 1, pp. 1-14, 1990, Scientific American Medicine Inc, New York, New 
York. 
111. Yanaga K, Podesta L, Broznick B, Stieber AC, Shapiro R, Makowka L: Multiple organ recovery 
for transplantation. From: Atlas of Organ Transplantation. Starzl TE. Shapiro R. Simmons RL 
(t!ds). Chapter 3, pp.3.2-3.49. 1992, Gower Medical Publishing, New York. New York. 
112. p~hwartz ME, Podesta L, Morris M. Makowka L, Miller CM: Donor management. techniques 
and procurement. From: The Handbook of Transplantation Management. Makowka L (ed), 
Chapter 2, pp.44-71, 1991, R.G. Landes Company, Austin, Texas. 
113. Marsh CL, Perkins lD, Sutherland DE, Corry Rl, Sterioff S: Combined hepatic and 
pancreaticoduodenal procurement for transplantation. Surg Gynecol Obstet 168 :254-258, 1989. 
114. Esquivel CO. Nakazato PZ, Concepcion W: Liver transplantation. Modern techniques in donor 
and recipient operations. From: Surgical Technology International Braverman MH (ed), 1992, 
pp.315-321, San Francisco. California. 
115. Starzl TE. Halgrimson CG, Koep U. Weil R III, Taylor PD: Vascular homografis from 
~adaveric organ donors. Surg Gynecol Obstet 149:76-77. 1979. 
116. Todo S. Makowka L, Tzakis AG, Marsh lW Jr, Karrer FM. Armany M. Miller C. Tallent MB, 
Esquivel CO, Gordon RD. Iwatsuki S, Starzl TE: Hepatic artery in liver transplantation. 
Transplant Proc 19:2406-2411. 1987. 
117. Tzakis A. Mazzaferro V. Pan C. Gordon RD. Todo S, Makowka L. Starzl TE: Renal artery 
reconstruction for harvesting injuries in kidney transplantation: With particular reference to the 
use of vascular allografts. Transplant International 1:80-85, 1988. 
118. Tzakis A. Todo S. Starzl TE: The anterior route t()r arterial graft conduits in liver transplantation. 
Transplant International (Letter to the Editor), 2:121, 1989. 
I 19. Stieber AC, Zetti G, Todo S, Tzakis AG, Fung J, Marino IR, Casavilla A, Selby R, Starzl TE: 
The spectrum ofportaJ vein thrombosis. Ann Surg 213:199-206, 1991. 
GROUP 
Amish 
Baha'i 
Baptist 
Buddhist Church of America 
Christian Sciences 
Church of Jesus Christ of 
Latter Day Saints 
Episcopal Church 
Evangelical Covenant Church 
Greek Orthodox Church 
Gypsies 
Hinduism 
Islam 
Jehovah's Witness 
Judaism 
Protestant Denominations 
ReliJ.:ious Society of Friends 
(Quakers) 
Roman Catholic Church 
Unitarian Universalist 
United Methodist Church 
TABLE 1 
DONATION 
Reluctant if transplant 
outcome uncertain 
Acceptable 
Individual decision 
Individual decision 
Individual decision 
Individual decision 
EncourJged 
Encour,lged 
Acceptable ( although not for 
research) 
Against 
Individual decision 
Acceptable (organs of Moslem 
donors must be transplanted 
immediately, and not stored in 
organ banks) 
Individual decision (not 
encour.1ged) 
Encour.1ged 
Individual decision 
Individual decision 
Encour.1ged 
Acceptable 
Encour.1ged 
TRANSPLANTATION 
Acceptable for the well-being 
of the candidate 
Acceptable 
Acceptable 
Buddha's teachings on the 
middle path (i.e., the 
avoidance of extremes) could 
be applicable to this 
Individual decision 
Individual decision 
Encoumged 
Encouraged 
Acceptable for the well-being 
of the candidate 
Against 
Individual decision 
Acceptable 
May be considered acceptable 
(organs should be completely 
drdined ot' blood before 
trdnsplantation) 
Encour.1ged 
Acceptable 
Individual decision 
Acceptable 
Acceptable 
Acceptable 
D
on
or
 In
fo
rm
at
io
n 
D
on
or
 1
0'
 
UN
O
S 
10
. 
D
on
or
 In
fo
rm
at
io
n 
D
on
or
 1
0#
 
R
ac
e:
 _
_
_
 
_
 
Ad
m
itt
in
g 
D
at
e:
 _
_
_
 
_
 
R
ec
ov
er
y 
D
at
e:
 _
_
_
 
_
 
H
os
pi
ta
l: 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
N
am
. 
Ag
e 
S
el
: _
_
_
 
_
 
D
at
e 
o
f B
,rl
h:
 _
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
R
ef
er
ra
l D
al
e:
 _
_
_
 
_
 
C
la
m
p 
T,
m
e:
 _
_
_
_
 AM
 
PM
 
C
he
s[ 
e
lf
: 
_
_
_
_
_
 
_
 
LE
 T
yp
e'
 
W
T 
HT
 
Go
rlh
: 
R
C
IB
R
R
: 
LC
IB
LR
: 
"
'B
O
: 
_
_
_
 
H
L"
': 
_
_
_
 
D
R
: 
H
O
lp
U
al
 H
I.
to
ry
 (I
nc
 tu
de
 E
.R
., 
V
IS
, A
rr
 ..
 ll
, O
.R
. P
ro
ce
du
r •
•
 ,
 
In
ju
rie
s, 
In
le
ct
lo
n,
 e
e
l.)
 
N
el
t o
f 
K,
n:
 
C
ity
/S
ta
te
: _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
R
el
al
oo
ns
hi
p.
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
 
R
ef
er
re
d 
By
: _
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
Ad
dr
es
s:
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
P
ho
ne
 .
: 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
Pr
og
ra
m
: 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
EK
G
, E
c
h
o
. 
C
lr
dl
lc
 C
on
lu
ll
: 
Pr
og
ra
m
 2
4 
hr
 .
: 
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
N
el
t o
f K
in
 P
ho
ne
: 
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
A
lle
nd
in
g:
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
C
he
m
l.
I,
le
. 
_
 
.
.
.
 -
-
.
 
-
-
-
-
-
-
-
-
-
~
 
-
-
~
 
C
on
su
lti
ng
: _
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
D
al
. 
D
a
l' 
D
al
e 
M
ed
ic
al
 R
ec
or
ds
 N
o.
: 
_
_
_
_
_
_
_
_
_
_
_
 
_
 
P
ro
no
un
ce
m
en
t D
at
e:
 
Ti
m
e:
 _
_
_
_
 
_
 
BU
N 
C
ol
or
 
pH
 
C
re
at
 
A
pp
ea
r 
P
02
 
T 
Bo
l 
pH
 
P
C
02
 
C
on
le
nt
 F
or
: _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 _
 
o
 B
ol 
Sp
 G
ra
v 
02
 S
al
 
SG
O
T 
G
lu
co
s.
 
F
I0
2 
C
.u
l.
o
tD
 ••
 t
h
~
·
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
SG
PT
 
Pr
ot
ei
n 
PE
EP
 
lD
H
 
Bl
oo
d 
VT
 
P
il
I 
.
.
.
.
 dl
ca
l H
llt
o
ry
: (
Co
m
pl
.t.
 h
llt
o
ry
 p
l.a
s.
) 
G
G
T 
AB
C 
R
al
e 
H
ea
rt 
D
is
ea
se
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
A
m
yl
as
e 
W
BC
 
N
a
. 
LI
ve
r 
D
is
ea
se
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
CP
K 
E
p'
lh
 
K
. 
R
en
al
 D
is
ea
se
: 
(Y
IN
) 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
D
ia
be
te
s:
 (Y
IN
) _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
G
lu
co
se
 
C
as
ts
 
C
I·
 
I:i9
.b
IH
CI
 
Ba
ct
 
Ca
 +
+
 
PT
 
N
eu
ro
lo
gi
ca
l: 
(Y
IN
) _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
p
n
 
C
an
ce
r: 
(Y
IN
) 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
P
ia
l 
Lu
ng
 D
is
ea
se
: (
Y/
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
W
B
e 
Ar
th
rIt
is
 o
r 
JO
int
 D
is
ea
se
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
B
lo
od
 P
re
 ••
 u
re
 
U
ri
ne
 O
ut
pu
t 
M
.d
. D
ur
in
g 
AD
M
 
(N
Ol
I I
:P
c 
to
.T
lm
.) 
(N
o'
. A
n
u
rl
./
O
tlg
ur
l.)
 
R
ec
en
l F
lu
 ·I
ik
e 
Sy
m
pt
om
s 
(Y
IN
) _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
U
ne
lp
la
in
ed
 W
ei
gh
l L
os
s:
 (Y
IN
) _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
 
To
XI
C 
E I
po
su
re
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
D
ru
g 
U
se
: P
re
sc
rIb
ed
 o
r 
O
th
er
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
Al
co
ho
l A
bu
se
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
 
Bl
oo
d 
& 
Bl
oo
d 
P
ro
du
c"
 
Sm
ok
er
 (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
Bl
oo
d 
Tr
an
sl
us
io
n 
H
is
to
ry
: (
 • 
2 
yr
s.
) (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
 
P.
ev
io
us
 S
ur
ge
ry
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
_
 
Se
ro
lo
gy
 
Im
m
un
Iz
at
io
n 
or
 V
ac
ci
na
te
d:
 ( 
I 
6 
m
o
.) 
(Y
IN
) _
_
_
_
_
_
 ~
-
-
-
-
-
_
_
_
_
_
_
_
_
_
_
_
 
_
 
Tr
av
el
 o
u
ts
id
e 
U
S
.A
 s
In
ce
 1
97
7:
 (Y
IN
) _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
D
a
ll 
Ti
m
e 
re
s
t 
P
re
 
Po
st
 R
es
ul
t 
lo
ca
l/l
m
po
rl 
R
ep
or
te
d 
By
 
R
ep
or
te
d 
To
 
R
P
R
IV
D
R
l 
H
om
os
el
ua
l o
. 
B
is
el
ua
l: 
(Y 
IN
) _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
H
B 
.
.
.
.
 g 
R
ec
ei
ve
d 
pi
t·h
G
h:
 (Y
IN
) 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
H
 ...
.
.
.
 
R
ec
en
t 
in
fe
ct
io
ns
: 
(Y
IN
) (
if 
ye
s 
gi
ve
 tr
ea
tm
en
t) 
H
IV
 
H
Tl
V
·1
 
G
 I.
 D
Is
or
de
rs
: (
YI
N)
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
CI
AV
 
H
eV
 
H
em
at
ol
og
ic
 D
Is
or
de
rs
: (
YI
N)
 
Un
de
r 
Ph
ys
ic
ia
n·
s 
C
ar
e:
 (Y
IN
) _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
C
ul
tu
re
. (
Bl
oo
d,
 U
ri
ne
, S
pu
tu
m
) D
.l
e,
 R
e.
u
lt
. 
Ph
yS
IC
Ia
n.
 P
ho
ne
 t
. 
Ad
dr
es
s:
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
_
 
TABLE m 
OrgantTissue Age (year) 
Heart .:5. 60a 
Heart-lungs .:5. 60a 
Lungs .:5. 60a 
Kidney 1 montb-75a 
Liver .=:;. 75a 
Pancreas .=:;. 65a 
Intestine b 
Bone 15-65 
Bone marrow .=:;. 75 
Cornea 1-65 
Skin 15-65 
Heart valves .:5. 55 
aDonors beyond these age limits could be accepted on the bases of the individual organ function. 
~o age limits have been set for intestinal donors. Intestines should be available from most organ donors 
and are always evaluated on an individual bases. 
Recovery Data Donor 10# 
Surgeons Renal: Assistlng: __________________ _ 
HepatiC: 
Cardiac: 
Heart/Lung: 
Pancreas: 
Coordlnato rslT echnicians (Ti ssue): 
In O.R. ____ A.. Incision ____ AM Depart O.R. (0) _____ A .. 
PM 
Depart O.R. (T) ____ AM 
Pt.I PM PM 
Condition During Surgery (Include: Blood Pressure, Urine Output, Complications, 
Comments) 
Operating Room Drugs (include dosage and time) 
Methyprednisolone: _____ _ Mannitol: ________ _ Furosemide: _________ _ 
Heparin: ________ _ Vasodilator: Blood Products ________ _ 
Antibiotics: ________ _ Others: __________________________ _ 
Nephrectomy Data Hepatectomy Data Cardiectomy Data 
En Bloc: YIN In Situ: YIN Precool Start ________ Infusion Start: ______ _ 
Flush Sol'n: _______ Vol: Sol'nNol: _________ Sol'n/Vol. _______ _ 
Final Flush (Sol'n Vol): ______ _ Portal Flush Start: ______ Ciampa Off: _______ _ 
Storage Sol'n: _________ _ 
Art Clamp: 
Flush Start 
Flush End: 
Warm Ischemia Time 
Clamps Off: 
Cold Ischemia Time 
R 
Single or Double Lung Data 
L 
Sol'nNol: Cold Ischemia Time 
Aortic Flush Start: ______ Heart Lung Data 
Sol'nNol: -I-nf-u-s-io-n-S-t-a"';rt:;'(-R-) ::::::::::-: 
Final Flush (Sol'nNol) _____ Sol'nVol: ________ _ 
Ciampa Off: ________ Infusion Start (L) _____ _ 
Cold Ischemia Time _____ SoI'n/Vol: ________ _ 
Anatomy: _________ Clamps Off: _______ _ 
Cold Ischemia Time 
Pancreas Data 
Infusion Start: ____________ _ Infusion Start: ______________ _ 
Sol'nNol. ______________ _ Sol'nNo!. ________________ _ 
Clamps Ott: _____________ _ Final Flush; (Sol'nNol) ___________ _ 
Cold Ischemia Time Clamps Ott: _______________ _ 
Cold Ischemia Time 
Anatomy ________________ _ 
Renal Anatomy 
L D 
G'ODSV Results: ___________________________________ _ 
Organs and Tissues Recovered (Check appropriate box and circle "T"lor Transplant. 'R" lor Research) 
o R·KI T/R 0 L·KI T/R 0 LI T/R 0 LU T/R 0 PA T/R 0 HR T/R 0 HV T/R 0 MV T/R 0 Bon .. T/R 
o BM r,R 0 Veins r,R 0 Skin r/R 0 Cornea T/R DINT T/R 0 Other riR 
TABLE IV 
4800 
4200 
CI) 3600 
~ 
o 5 3000 
Q 
a 2400 
~ 
~ 1800 
E 
~ 1200 
600 
a 
Organ Donors (USA) 
80 81 82· 83 84 85 86 87 88 89 90 91 92 
Year 
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